Home > Dermatology > EADV 2019 > Emerging Therapies > Small molecules: interesting novel treatment options in AD

Small molecules: interesting novel treatment options in AD

Presented By
Prof. Tilo Biedermann, Helmholtz Center Munich, German
Conference
EADV 2019
There is a high need for oral treatments for atopic dermatitis (AD) that cannot be controlled with local therapy. Both phosphodiesterase (PDE) inhibitors and Janus kinase (JAK) inhibitors are interesting approaches [1]. PDE4 is involved in the regulation of pro-inflammatory cytokines via the degradation of cyclic adenosine monophosphate. Targeting PDE4 reduces the production of pro-inflammatory mediators in AD and may be an interesting treatment target with a favourable safety profile [2]. Apremilast, an orally available PDE4 inhibitor, is approved for the treatment of adults with moderate-to-severe psoriasis and active psoriatic arthritis. This immune modulator regulates a number of the pro-inflammatory signals involved in AD, including IL-17, IL-22, IL-13, and IL-31 [3]. A phase 2 study published earlier this year evaluated the treatment effect of 30 mg and 40 mg of apremilast on skin clearance, assessed in EASI percentage change from baseline in ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on